418 studies found for:    leukemia [CONDITION] AND child [AGE-GROUP] | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
leukemia [CONDITION] AND child [AGE-GROUP] | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   MDS;   Refractory Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Non-Hodgkin's Lymphoma;   Leukemia;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndromes
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
2 Recruiting Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Conditions: Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myeloproliferative Diseases;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome
Interventions: Drug: Fludarabine monophosphate;   Drug: Busulfan;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
3 Not yet recruiting Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
4 Recruiting Cord Blood Transplant
Conditions: Chronic Myelogenous Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome;   Multiple Myeloma;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   Acute Lymphocytic Leukemia (ALL);   Severe Aplastic Anemia
Intervention: Genetic: umbilical cord transplant (UCB)
5 Recruiting Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Conditions: Leukemia, Myelogenous, Chronic;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelogenous, Acute;   Myeloproliferative-Myelodysplastic Diseases;   Lymphoma, Malignant
Interventions: Drug: Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;   Drug: Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies;   Other: Hematopoietic Progenitor Cell Transplantation (HPCT);   Radiation: CNS radiation treatment for ALL with prior CNS disease patients
6 Recruiting Dose Escalation Study of EPZ-5676 in Pediatric Patients With Leukemias Bearing a Rearrangement of the MLL Gene
Conditions: Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Acute Leukemias
Intervention: Drug: EPZ-5676
7 Recruiting Stem Cell Transplant for Hematological Malignancy
Conditions: Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
8 Recruiting Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Conditions: Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Marginal Zone Lymphoma;   Follicular Lymphomas;   Large-cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   High Grade Lymphomas;   Mantle-cell Lymphoma;   Lymphoplasmacytic Lymphoma
Intervention: Biological: HSC835
9 Recruiting Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Conditions: Acute Undifferentiated Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies;   Childhood Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hairy Cell Leukemia;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Neoplasm of Uncertain Malignant Potential;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
10 Recruiting Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic and Lymphoid Cell Neoplasm;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Hodgkin Lymphoma;   Small Lymphocytic Lymphoma;   T-Cell Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
11 Recruiting Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Conditions: Adult Acute Lymphoblastic Leukemia;   Adult Acute Myeloid Leukemia;   Adult Diffuse Large B-Cell Lymphoma;   Aggressive Non-Hodgkin Lymphoma;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Diffuse Large B -Cell Lymphoma;   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Stage I Adult Hodgkin Lymphoma;   Stage I Aggressive Adult Non-Hodgkin Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Diffuse Large B-Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Contiguous Adult Aggressive Non-Hodgkin Lymphoma;   Stage II Contiguous Mantle Cell Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage II Non-Contiguous Aggressive Adult Non-Hodgkin Lymphoma;   Stage II Non-Contiguous Mantle Cell Lymphoma;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Aggressive Adult Non-Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Diffuse Large B-Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Aggressive Adult Non-Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Diffuse Large B-Cell Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Drug: Atorvastatin Calcium;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
12 Not yet recruiting Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Fludarabine monophosphate;   Drug: Bendamustine;   Biological: Activated T-Cell Infusion;   Drug: Lenalidomide;   Behavioral: Phone Calls
13 Recruiting Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
14 Unknown  Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT
Conditions: Acute Lymphoblastic Leukemia;   Leukemia Acute Myeloid - AML;   Non-Hodgkin Lymphoma;   Myelodysplastic Syndromes
Intervention: Biological: TCR alfa beta T cell depletion
15 Recruiting Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Conditions: Tumors;   Malignant Melanoma;   Hematological Malignancies;   Myelogenous Leukemia, Chronic;   Leukemia, Lymphoblastic, Acute
Interventions: Procedure: Immunoablative Hematopoietic PBSC Transplant;   Procedure: Busulfan pharmacokinetics;   Radiation: CNS prophylaxis radiation
16 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Melphalan;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
17 Recruiting Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Conditions: Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia
Intervention: Biological: CD19 Specific CAR T Cells
18 Recruiting Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Conditions: Prolymphocytic Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Chronic Lymphocytic Leukemia;   T-Cell Prolymphocytic Leukemia
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Therapeutic Autologous Lymphocytes;   Radiation: Total-Body Irradiation
19 Recruiting Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Conditions: Acute Lymphoblastic Leukemia (ALL);   Chronic Lymphocytic Leukemia (CLL);   Non Hodgkin's Lymphoma
Intervention: Genetic: CD19CAR/virus specific T cells
20 Not yet recruiting Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Conditions: Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Myeloproliferative Disorders
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years